Drug Utilization Research / Health policy and governance

((B-057)) (B-057) DARWIN EU® - Trends of use of Glucagon-like peptide-1 Receptor Agonists in real-world data from five European countries

((B-058)) (B-058) DARWIN-EU ®- Antipsychotic prescribing in people with dementia in Europe: a descriptive analysis of trends and patient characteristics

((B-059)) (B-059) The impact of drug shortages in the use of medicines across 52 real-world data sources in 19 countries in Europe and North America

((B-060)) (B-060) Opioid Agonist Treatment Dispensing Trends Between 2018 and 2022 Across Six Canadian Provinces

((B-061)) (B-061) Utilization of Nationwide Claims Data Mapped to OMOP Common Data Model to Enhance Post-Marketing Drug Safety Studies

((B-062)) (B-062) Impact of Medicaid Mandatory Medication-Assisted Treatment (MAT) Benefit on Opioid Use Disorder Treatment Utilization, 2018-2022

((B-063)) (B-063) Off-label Use of Glucagon-like Peptide 1 Agonists (GLP-1): Evidence from Medicare Part D

((B-064)) (B-064) Impact of supply chain disruptions and drug shortages on drug utilization: a scoping review

((B-065)) (B-065) Regional Impact of the COVID-19 Pandemic on Polypharmacy Reduction Policies in Japan: A Nationwide Serial Cross-Sectional Study

((B-066)) (B-066) Impact of the antibiotics management policy and the COVID-19 pandemic on antimicrobial usage in Japan: A nationwide serial cross-sectional study

((B-067)) (B-067) Assessing the Impact of COVID-19 Lockdown on Methadone and Buprenorphine Prescriptions in England: An Interrupted Time Series Analysis

((B-068)) (B-068) Impact of andexanet alfa introduction on mortality and thromboembolic events, before and after Tuscan guidelines, in patients treated with rivaroxaban or apixaban with major bleeding

((B-069)) (B-069) Differences in Characteristics and Clinical Benefits of Pivotal Trials Supporting Regulatory Approval of “Breakthrough” Drugs in the US and China

((B-070)) (B-070) Applicability of Real-World Data for Healthcare Decision-Making: A Review and Comparison of Guidelines

((B-071)) (B-071) Uncertainty in Pre-approval and Post-approval Clinical Evidence of Drugs Granted Conditional Approval in China

((B-072)) (B-072) Prescribing pattern of medicines at orthopedics outpatient department of a tertiary care hospital

((B-073)) (B-073) Pharmacists' Perspectives on Antibiotic Shortages: Implications for Clinical Practice in Australia

((B-074)) (B-074) From Catalogue to Clarity: Characterizing Chinese Data Sources for Post-Authorization Real-World Studies

((B-075)) (B-075) Persistence of Medical Marijuana Use among Certified Patients in the State of Florida

((B-076)) (B-076) The Inflation Reduction Act Lowers Out-of-Pocket Costs for Orally-Administered Blood Cancer Therapies

((B-077)) (B-077) Evolving Landscape of Post-Marketing Surveillance (PMS) Studies in Japan Utilising Secondary Real-World Data (RWD)

((B-078)) (B-078) Stakeholder Analysis of Responses to the FDA’s Discussion Paper on Artificial Intelligence and Machine Learning in Drug and Biological Product Development

((B-079)) (B-079) Characteristics of RWE used in Regulatory Decision-Making for Marketing Authorization Applications (MAAs)

((B-080)) (B-080) Evaluation of Real-World Evidence in Regulatory and HTA Submissions

((B-081)) (B-081) Impact of Hospital Market Concentration on Spatial Accessibility and Inequality of Antidepressants Before and After Volume-Based Procurement in China

((B-082)) (B-082) Assessing the Impact of Volume-Based Procurement on Antidepressant Accessibility and Inequality: A Four-City Cohort Study Using Drug Sales Data

((B-083)) (B-083) Use of Belatacept and Tacrolimus Among Kidney Transplant Recipients From 2011-2020: Comparing United States Renal Data System (USRDS) and Scientific Registry of Transplant Recipients (SRTR)

((B-084)) (B-084) Residential Proximity to the Coast and Antidepressant Medication Use: Moderating Effects of Seasonal Variation

((B-085)) (B-085) Estimating Travel Time and Spatial Access to Insulin in China Before and After National Volume-Based Procurement: A Geospatial Analysis

((B-086)) (B-086) Nervous System Medication Dispensing Patterns Following Teleconsultations in France from January 2021 to June 2023: A Repeated Cross-sectional Study Using the National Health Data System

((B-087)) (B-087) Missed Opportunities for Patient Recruitment in Clinical Trials for Rare Cancers

((B-088)) (B-088) The evolving landscape of clinical trials in Peru

((B-089)) (B-089) Optimizing Healthcare Outcomes in Ambulatory Patients through Clinical Pharmacist-Led Services